NFD
MCID: NPH018
MIFTS: 50

Nephrogenic Systemic Fibrosis (NFD)

Categories: Nephrological diseases, Rare diseases, Skin diseases

Aliases & Classifications for Nephrogenic Systemic Fibrosis

MalaCards integrated aliases for Nephrogenic Systemic Fibrosis:

Name: Nephrogenic Systemic Fibrosis 52 58 71
Nephrogenic Fibrosing Dermopathy 52 58 17 71
Nfd 52
Nsf 52

Classifications:

Orphanet: 58  
Rare skin diseases


External Ids:

UMLS via Orphanet 72 C1619692 C3888044
Orphanet 58 ORPHA137617
UMLS 71 C1619692 C3888044

Summaries for Nephrogenic Systemic Fibrosis

NIH Rare Diseases : 52 Nephrogenic systemic fibrosis is a condition that affects different parts of the body, particularly the skin. Symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures , and pruritis (itching). The skin findings are similar to those seen in patients with scleroderma . Nephrogenic systemic fibrosis was first described in 1997. Being exposed to gadolinium-containing contrast agents during MRI testing has been identified as a significant risk factor for development of this disease.

MalaCards based summary : Nephrogenic Systemic Fibrosis, also known as nephrogenic fibrosing dermopathy, is related to scleroderma, familial progressive and keloid disorder, and has symptoms including pruritus and exanthema. An important gene associated with Nephrogenic Systemic Fibrosis is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Protein Kinase Inhibitors and Imatinib Mesylate have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and testes, and related phenotypes are cardiovascular system and cellular

Wikipedia : 74 Nephrogenic systemic fibrosis is a rare syndrome that involves fibrosis of skin, joints, eyes, and... more...

Related Diseases for Nephrogenic Systemic Fibrosis

Diseases related to Nephrogenic Systemic Fibrosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 191)
# Related Disease Score Top Affiliating Genes
1 scleroderma, familial progressive 31.2 EDN1 CCN2
2 keloid disorder 30.6 TGFB1 SMAD3
3 chronic kidney disease 30.4 TGFB1 SPP1 EPO EDN1 CCN2
4 kidney disease 30.2 TGFB1 SPP1 EPO EDNRA EDN1 CCN2
5 glomerulonephritis 29.5 TGFB1 SPP1 SMAD2 CCN2
6 pulmonary fibrosis 28.9 TIMP1 TGFB1 SMAD7 SMAD3 EDN1 DCN
7 localized scleroderma 28.9 TGFB1 SMAD7 SMAD4 SMAD3 DCN CCN2
8 pulmonary hypertension 28.8 TIMP1 SMAD4 SMAD3 SMAD2 EDNRA EDN1
9 tetanus 11.7
10 transient cerebral ischemia 11.6
11 neuronal intranuclear inclusion disease 11.5
12 schizophrenia 11.4
13 foodborne botulism 11.3
14 fibrosis of extraocular muscles, congenital, 1 11.1
15 migraine with or without aura 1 11.1
16 hemophagocytic lymphohistiocytosis, familial, 4 11.1
17 cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome 11.1
18 leukodystrophy, hypomyelinating, 6 11.1
19 intestinal botulism 11.1
20 wound botulism 11.1
21 infant botulism 11.1
22 hypomyelinating leukodystrophy 11.1
23 blepharospasm 11.1
24 end stage renal disease 10.7
25 acute kidney failure 10.6
26 systemic scleroderma 10.5
27 scleromyxedema 10.5
28 polykaryocytosis inducer 10.5
29 pseudoxanthoma elasticum 10.4
30 acute kidney tubular necrosis 10.4
31 lupus erythematosus 10.4
32 dowling-degos disease 1 10.4
33 pauci-immune glomerulonephritis 10.3 SMAD2 CCN2
34 diffuse scleroderma 10.3 TGFB1 EDN1 CCN2
35 stachybotrys chartarum 10.3 CXCL2 CCL7
36 eisenmenger syndrome 10.3 TGFB1 EDN1
37 idiopathic interstitial pneumonia 10.3 TGFB1 EDN1 CCN2
38 hyperphosphatemia 10.2
39 metabolic acidosis 10.2
40 hepatorenal syndrome 10.2
41 scleredema adultorum 10.2
42 skin disease 10.2
43 liver disease 10.2
44 dermatomyositis 10.2
45 uveitis 10.2
46 antiphospholipid syndrome 10.2
47 mucinoses 10.2
48 granuloma annulare 10.2
49 rapidly progressive glomerulonephritis 10.2
50 homologous wasting disease 10.2

Graphical network of the top 20 diseases related to Nephrogenic Systemic Fibrosis:



Diseases related to Nephrogenic Systemic Fibrosis

Symptoms & Phenotypes for Nephrogenic Systemic Fibrosis

UMLS symptoms related to Nephrogenic Systemic Fibrosis:


pruritus, exanthema

MGI Mouse Phenotypes related to Nephrogenic Systemic Fibrosis:

45 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.53 CCN2 CXCL2 EDN1 EDNRA EPO F13A1
2 cellular MP:0005384 10.4 CCN2 DCN EDNRA EPO MAPKAP1 PIK3CA
3 homeostasis/metabolism MP:0005376 10.4 CCN2 DCN EDN1 EDNRA EPO F13A1
4 growth/size/body region MP:0005378 10.39 CCN2 DCN EDN1 EDNRA MAPKAP1 PIK3CA
5 endocrine/exocrine gland MP:0005379 10.37 CCN2 DCN EDN1 EDNRA F13A1 PIK3CA
6 mortality/aging MP:0010768 10.36 CCN2 DCN EDN1 EDNRA EPO F13A1
7 embryo MP:0005380 10.31 CCN2 EDN1 EDNRA EPO MAPKAP1 PIK3CA
8 hematopoietic system MP:0005397 10.31 DCN EDNRA EPO F13A1 SMAD2 SMAD3
9 immune system MP:0005387 10.29 DCN EDNRA EPO PIK3CA SMAD2 SMAD3
10 craniofacial MP:0005382 10.28 CCN2 DCN EDN1 EDNRA SMAD2 SMAD3
11 integument MP:0010771 10.24 CCN2 DCN EDNRA EPO PIK3CA SMAD2
12 digestive/alimentary MP:0005381 10.23 CCN2 DCN EDN1 EDNRA SMAD2 SMAD3
13 muscle MP:0005369 10.09 DCN EDN1 EDNRA EPO PIK3CA SMAD4
14 neoplasm MP:0002006 10.06 DCN PIK3CA SMAD2 SMAD3 SMAD4 SPP1
15 liver/biliary system MP:0005370 10.02 CCN2 EPO SMAD2 SMAD3 SMAD4 SPP1
16 normal MP:0002873 9.97 CCN2 DCN EDN1 EDNRA EPO SMAD2
17 reproductive system MP:0005389 9.96 DCN F13A1 PIK3CA SMAD2 SMAD3 SMAD4
18 renal/urinary system MP:0005367 9.92 DCN EDN1 EDNRA SMAD3 SMAD4 SPP1
19 respiratory system MP:0005388 9.81 CCN2 DCN EDNRA EPO F13A1 SMAD2
20 skeleton MP:0005390 9.8 CCN2 CXCL2 DCN EDN1 EDNRA EPO
21 vision/eye MP:0005391 9.32 CCN2 DCN EDNRA MAPKAP1 PIK3CA RCN1

Drugs & Therapeutics for Nephrogenic Systemic Fibrosis

Drugs for Nephrogenic Systemic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 28)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Protein Kinase Inhibitors Phase 3
2 Imatinib Mesylate Phase 3 220127-57-1 123596
3 Liver Extracts Phase 3
4 Hematinics Phase 3
5 Ferrosoferric Oxide Phase 3
6 Pharmaceutical Solutions Phase 3
7 Parenteral Nutrition Solutions Phase 3
8
Sodium citrate Approved, Investigational Phase 2 68-04-2
9
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
10
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
11 Plasma-lyte 148 Phase 1, Phase 2
12 Citrate Phase 2
13 Phosphodiesterase 5 Inhibitors Phase 2
14 Phosphodiesterase Inhibitors Phase 2
15 Vasodilator Agents Phase 2
16 Sildenafil Citrate Phase 2 171599-83-0
17 calcium heparin Phase 2
18
Doxorubicin Approved, Investigational Phase 1 23214-92-8 31703
19
Liposomal doxorubicin Phase 1 31703
20 Anti-Bacterial Agents Phase 1
21 Antibiotics, Antitubercular Phase 1
22
Iodine Approved, Investigational 7553-56-2 807
23 Anticoagulants
24 Chelating Agents
25 Calcium, Dietary
26 cadexomer iodine
27 Fluorodeoxyglucose F18
28
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Primovist/Eovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information. Completed NCT00908596 Phase 4 Gadoxetic acid disodium (Primovist, BAY86-4873)
2 Prospective Non-randomized (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Gadovist in Patients With Moderate to Severe Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information Completed NCT00828737 Phase 4 Gadobutrol (Gadovist, BAY86-4875)
3 A Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive OMNISCAN (Gadodiamide Injection) for Contrast-enhanced Magnetic Resonance Imaging. Completed NCT00908310 Phase 4 Omniscan
4 Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease Recruiting NCT02752191 Phase 4 ferumoxytol;gadofosveset
5 Use of Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) and Understanding Its Etiology Terminated NCT01078987 Phase 4
6 The Prevalence and Severity of Nephrogenic Systemic Fibrosis in Patients Whom Underwent Imaging With Gadollinium(MRI/MRA) in University Hospital of Tehran Heart Center in 2003-2008 Unknown status NCT01359345 Phase 2, Phase 3 gadollinum
7 An Open Label Clinical Trial of Imatinib Mesylate(Glivec)in Patients With Moderate to Severe Nephrogenic Systemic Fibrosis Completed NCT00981942 Phase 3 Imatinib mesylate (Glivec)
8 A Multicenter, Open-label Phase III Study of the Efficacy and Safety of Primovist as a Contrast Agent for Enhanced MR Imaging of Focal Liver Lesions in Chinese Patients Completed NCT00526188 Phase 3 Gadoxetic Acid Disodium (Primovist, BAY86-4873)
9 Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease Enrolling by invitation NCT02954510 Phase 3 ferumoxytol
10 An Open Label Phase 2 Pilot Study to Determine the Safety, Efficacy and Tolerability of Gleevec (Imatinib Mesylate) in the Treatment of Nephrogenic Systemic Fibrosis Completed NCT00677092 Phase 2 Imatinib mesylate
11 The Effects of Balanced and Unbalanced Crystalloids and Colloids on Serum Biochemistry and Visceral Blood Flow: A Two Phase, Double Blind, Randomised Crossover Study Completed NCT01087853 Phase 1, Phase 2 Crystalloid;Colloid
12 Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel Recruiting NCT04058132 Phase 2 Sildenafil Citrate 50Mg Tab;Gadolinium contrast infusion
13 An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis Active, not recruiting NCT03364270 Phase 2 PET/CT Imaging with [F-18] RGD-K5
14 The Use of Ferumoxytol (Feraheme) for Whole Body Magnetic Resonance Angiography in Hereditary Hemorrhagic Telangiectasia Completed NCT02977637 Phase 1
15 The Magnetic Resonance Imaging Evaluation of Doxorubicin Cardiotoxicity Completed NCT00530101 Phase 1 Doxorubicin
16 Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Enrolling by invitation NCT03173066 Phase 1 Ferumoxytol
17 Using Novel Blood and Imaging Biomarkers to Better Understand the Pathophysiology of Paediatric Dilated Cardiomyopathy Unknown status NCT02001961
18 Feasibility Study of MRI Imaging on Parotid Gland Stimulation Unknown status NCT02294838
19 Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT Unknown status NCT02592304
20 Validation of a Questionnaire as a Screening Tool to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis Completed NCT00869479
21 A Prospective Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 4 to 5 Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents Within the Past 10 Years Completed NCT00773409
22 Nephrogenic Systemic Fibrosis and Gadolinium—A Medical Record Review With Analysis of Existing Skin and Other Tissue Specimens to Assess Potential Causative or Associated Factors Completed NCT01014754
23 Prospective Non-randomized Observational (Pharmacoepidemiologic) Cohort Study (Open-label, Multicenter) to Assess the Magnitude of Potential Risk With the Administration of Magnevist® Injection in Patients With Moderate Renal Impairment for the Development of Nephrogenic Systemic Fibrosis (NSF) Based on Diagnostically Specific Clinical and Histopathologic Information. Completed NCT00744939 Gadopentetate dimeglumine (Magnevist, BAY86-4882)
24 A Phase 4, Open-Label, Prospective Evaluation of the Incidence of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate to Severe Kidney Disease Undergoing Magnetic Resonance Imaging (MRI) With Ablavar (Gadofosveset Trisodium) in Routine Clinical Practice Completed NCT01135316 Ablavar
25 Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration Completed NCT01467271
26 A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of MultiHance Completed NCT00600951
27 A Prospective Cohort Study Evaluating the Incidence of Nephrogenic Systemic Fibrosis in Patients With Stages 3 to 5 Chronic Kidney Disease Undergoing MRI With the Injection of ProHance Completed NCT00600834
28 Comparison of Non-contrast Renal Artery Magnetic Resonance Angiography With Contrast-enhanced CT Angiography Completed NCT01576835
29 Exploratory Evaluation of the Potential for Long-term Retention of Gadolinium in the Bones of Patients Who Have Received Gadolinium Based Contrast Agents According to Their Medical History Completed NCT01853163
30 Randomized, Clinical Study to Compare Accuracy of 1.5 T Versus 3 T Magnetic Resonance Arterial Spin Labeling to Measure Renal Blood Flow and the Changes of Renal Perfusion Caused by Physiological Stress (Cold Pressor Test). Completed NCT02746549
31 Prospective Clinical Trial to Investigate Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced) Completed NCT01132339
32 Use of Ferumoxytol Enhanced Magnetic Resonance Angiography for Cardiovascular Assessment in Late-stage Chronic Kidney Disease Completed NCT02997046
33 Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study Recruiting NCT01910818
34 A Prospective Multicenter Cohort Study Evaluating the Long Term Retention of Gadolinium in Human Bone and Skin After the Retrospective Administration of MultiHance or ProHance in Comparison With a Control Group Receiving No Exposure to Gadolinium Recruiting NCT03108378
35 Pilot Study Using Parametric PET to Assess Early Treatment Response to Targeted Therapy for Renal Cell Carcinoma Recruiting NCT04020978
36 A Prospective Study to Evaluate Quantitative Non-Contrast Perfusion Using Arterial Spin Labeled Magnetic Resonance (MR) Imaging for Assessment of Therapy Response in Glioblastoma Active, not recruiting NCT03922984
37 Kidney Transplantation and Renal and Myocardial Perfusion Active, not recruiting NCT02960802
38 Imaging Endolymphatic Hydrops at 7T MRI: Validation of Internal Inner Ear Structures on T2w Imaging as Markers of Endolymphatic Hydrops and a Comparison of Diagnostic Outcomes With 3T MRI Not yet recruiting NCT04370366
39 A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging Withdrawn NCT00811863
40 A Prospective Observational Study on the Use of Iodinated Contrast for AV Fistula Salvage in Stage 4/5 CKD Using Bicarbonate Prophylaxis Withdrawn NCT00621972

Search NIH Clinical Center for Nephrogenic Systemic Fibrosis

Genetic Tests for Nephrogenic Systemic Fibrosis

Anatomical Context for Nephrogenic Systemic Fibrosis

MalaCards organs/tissues related to Nephrogenic Systemic Fibrosis:

40
Skin, Kidney, Testes, Liver, Eye, Bone, Heart

Publications for Nephrogenic Systemic Fibrosis

Articles related to Nephrogenic Systemic Fibrosis:

(show top 50) (show all 963)
# Title Authors PMID Year
1
Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment. 61
32112811 2020
2
Risk for Nephrogenic Systemic Fibrosis After Exposure to Newer Gadolinium Agents: A Systematic Review. 61
32568573 2020
3
Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology. 61
32565280 2020
4
Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis. 61
32452732 2020
5
Strategic reconstruction of macrophage-derived extracellular vesicles as a magnetic resonance imaging contrast agent. 61
32300771 2020
6
Risks and Benefits of Gadolinium-Based Contrast-Enhanced MRI. 61
32446430 2020
7
Risks and Benefits of Gadolinium-Based Contrast Enhanced MRI. 61
32446435 2020
8
Multimodal indirect imaging signs of pulmonary embolism. 61
31944831 2020
9
Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy? 61
31663374 2020
10
Sclerodermalike syndromes: Great imitators. 61
32513403 2020
11
Nephrogenic Systemic Fibrosis Risk Assessment and Skin Biopsy Quantification in Patients with Renal Disease following Gadobenate Contrast Administration. 61
32115422 2020
12
Gadolinium Retention and Breast MRI Screening: More Harm Than Good? 61
31799869 2020
13
Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study. 61
31287213 2020
14
Noncontrast Magnetic Resonance Angiography Clinical Application in Pre-Liver Transplant Recipients With Impaired Renal Function. 61
31715655 2020
15
Integration of gadolinium in nanostructure for contrast enhanced-magnetic resonance imaging. 61
31486295 2020
16
Radiocontrast Toxicity. 61
32147002 2020
17
The Risk of Nephrogenic Systemic Fibrosis in Group II and III Gadolinium-Based Contrast Agents. 61
32063014 2020
18
Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer. 61
31809230 2020
19
Feasibility of using half-dose Gd-BOPTA for delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at the knee, compared with standard-dose Gd-DTPA. 61
31141254 2020
20
The first case of coexistence of calciphylaxis and nephrogenic systemic fibrosis with different localizations in a hemodialysis patient. 61
31182286 2020
21
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. 61
31816007 2019
22
The extra miles on preventing nephrogenic systemic fibrosis. 61
31867242 2019
23
Contraindications and adverse effects in abdominal imaging. 61
31765455 2019
24
Is it time to relax nephrogenic systemic fibrosis guidelines and safely offer magnetic resonance imaging to more patients? 61
31867244 2019
25
Pictorial review on abdominal applications of ferumoxytol in MR imaging. 61
31378828 2019
26
Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging. 61
30796704 2019
27
Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study. 61
31272740 2019
28
Nephrogenic Systemic Fibrosis Is Mediated by Myeloid C-C Chemokine Receptor 2. 61
30978353 2019
29
Non-Contrast-Enhanced Carotid MRA: Clinical Evaluation of a Novel Ungated Radial Quiescent-Interval Slice-Selective MRA at 1.5T. 61
31395666 2019
30
The Transition from Metal-Based to Metal-Free Contrast Agents for T1 Magnetic Resonance Imaging Enhancement. 61
31380621 2019
31
Effects of gadolinium and gadolinium chelates on intracellular calcium signaling in sensory neurons. 61
31152851 2019
32
[Sclerosing skin diseases]. 61
31292667 2019
33
Diagnostic value of alternative techniques to gadolinium-based contrast agents in MR neuroimaging-a comprehensive overview. 61
31444580 2019
34
Updated Clinical Practice Guideline on Use of Gadolinium-Based Contrast Agents in Kidney Disease Issued by the Canadian Association of Radiologists. 61
31255393 2019
35
Gadolinium chloride promotes proliferation of HEK293 human embryonic kidney cells by activating EGFR/PI3K/Akt and MAPK pathways. 61
31286331 2019
36
A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. 61
31264946 2019
37
Virtual Elimination of Nephrogenic Systemic Fibrosis: A Medical Success Story with a Small Asterisk. 61
31268818 2019
38
Nephrogenic systemic fibrosis: the end of the story? 61
31559176 2019
39
Launching lollipops? Perforating osteoma cutis in nephrogenic systemic fibrosis. 61
31355484 2019
40
Calciphylaxis and nephrogenic fibrosing dermopathy with pseudoxanthoma elasticum-like changes: Successful treatment with sodium thiosulfate. 61
30663093 2019
41
Non-contrast-enhanced magnetic resonance imaging for visualization and quantification of endovascular aortic prosthesis, their endoleaks and aneurysm sacs at 1.5 T. 61
31075419 2019
42
Toxicological Risk Assessments of Iron Oxide Nanocluster- and Gadolinium-Based T1MRI Contrast Agents in Renal Failure Rats. 61
31141658 2019
43
Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation. 61
30801544 2019
44
[Kidney function in contrast media-enhanced imaging]. 61
31016343 2019
45
[Gadolinium deposition-"gadolinium deposition disease"]. 61
30963195 2019
46
Relaxivity and toxicological properties of manganese oxide nanoparticles for MRI applications. 61
31156805 2019
47
Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents. 61
30471330 2019
48
Noncontrast Magnetic Resonance Angiography for the Diagnosis of Peripheral Vascular Disease. 61
31088154 2019
49
Reductive microenvironment responsive gadolinium-based polymers as potential safe MRI contrast agents. 61
30773580 2019
50
Update on Gadolinium-Based Contrast Agent-Enhanced Imaging in the Genitourinary System. 61
30973785 2019

Variations for Nephrogenic Systemic Fibrosis

Expression for Nephrogenic Systemic Fibrosis

Search GEO for disease gene expression data for Nephrogenic Systemic Fibrosis.

Pathways for Nephrogenic Systemic Fibrosis

Pathways related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 TIMP1 TGFB1 SPP1 SMAD4 SMAD3 SMAD2
2
Show member pathways
13.68 TIMP1 TGFB1 SMAD4 SMAD3 EPO EDNRA
3
Show member pathways
13.5 TIMP1 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
4
Show member pathways
13.3 TIMP1 TGFB1 SMAD4 SMAD3 CXCL2 CCN2
5
Show member pathways
13.05 TGFB1 SPP1 SMAD4 SMAD3 SMAD2 PIK3CA
6
Show member pathways
12.85 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA
7
Show member pathways
12.82 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
8 12.78 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA EPO
9
Show member pathways
12.76 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA
10
Show member pathways
12.51 SMAD7 SMAD4 SMAD3 SMAD2 PIK3CA
11
Show member pathways
12.5 TGFB1 SMAD4 SMAD3 SMAD2
12
Show member pathways
12.45 TGFB1 SMAD4 SMAD3 SMAD2
13 12.36 TGFB1 SMAD4 SMAD3 SMAD2
14 12.36 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA
15
Show member pathways
12.35 SMAD7 SMAD4 SMAD3 SMAD2
16
Show member pathways
12.31 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
17 12.3 TGFB1 SMAD2 PIK3CA DCN
18 12.24 TGFB1 SMAD4 SMAD3 SMAD2 CCN2
19
Show member pathways
12.23 TGFB1 SMAD4 SMAD3 SMAD2
20 12.18 TGFB1 SMAD4 SMAD3 SMAD2
21 12.16 TGFB1 SMAD3 SMAD2 PIK3CA
22 12.11 SMAD4 SMAD3 SMAD2 PIK3CA
23
Show member pathways
12.09 TGFB1 SMAD4 SMAD3 PIK3CA
24 12.09 SPP1 SMAD4 SMAD3 SMAD2 CCN2
25 12.08 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2 CCN2
26 12.07 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
27 12 TGFB1 SMAD4 SMAD3 PIK3CA
28 11.98 TIMP1 PIK3CA EPO EDN1
29 11.92 TGFB1 SMAD4 SMAD3
30 11.9 TGFB1 PIK3CA CXCL2
31
Show member pathways
11.9 TGFB1 SMAD4 SMAD3 SMAD2
32 11.9 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
33
Show member pathways
11.88 TGFB1 SMAD4 SMAD3 SMAD2
34 11.87 TGFB1 SPP1 DCN
35 11.8 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA EDN1
36
Show member pathways
11.79 TGFB1 SMAD4 SMAD3 SMAD2
37 11.78 SMAD7 SMAD4 SMAD3 SMAD2
38 11.73 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
39 11.71 TGFB1 SMAD4 SMAD3 SMAD2
40 11.71 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2 DCN
41 11.69 SMAD4 SMAD3 EPO EDN1
42
Show member pathways
11.68 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
43
Show member pathways
11.62 TGFB1 SMAD4 SMAD3 SMAD2 PIK3CA
44 11.56 TGFB1 SMAD4 SMAD3
45
Show member pathways
11.54 SMAD4 SMAD3 SMAD2
46 11.4 TGFB1 SPP1 SMAD7 SMAD4 SMAD3 SMAD2
47 11.29 TGFB1 SMAD4 SMAD3 SMAD2
48
Show member pathways
11.24 TGFB1 SMAD7 SMAD4
49
Show member pathways
11.2 SMAD4 SMAD3 PIK3CA
50 11.19 SMAD4 SMAD3 SMAD2 CCN2

GO Terms for Nephrogenic Systemic Fibrosis

Cellular components related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 10.02 TIMP1 TGFB1 SPP1 EPO EDN1 DCN
2 extracellular region GO:0005576 10.02 TIMP1 TGFB1 SPP1 F13A1 EPO EDN1
3 collagen-containing extracellular matrix GO:0062023 9.8 TGM2 TGFB1 F13A1 DCN CCN2
4 extracellular matrix GO:0031012 9.78 TIMP1 TGFB1 DCN CCN2
5 transcription factor complex GO:0005667 9.76 SMAD7 SMAD4 SMAD3 SMAD2
6 platelet alpha granule lumen GO:0031093 9.61 TIMP1 TGFB1 F13A1
7 cell GO:0005623 9.56 TGM2 TGFB1 SMAD4 SMAD3 PIK3CA EDNRA
8 activin responsive factor complex GO:0032444 9.26 SMAD4 SMAD2
9 heteromeric SMAD protein complex GO:0071144 9.16 SMAD3 SMAD2
10 SMAD protein complex GO:0071141 8.8 SMAD4 SMAD3 SMAD2

Biological processes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2 EDN1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.11 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2 EPO
3 positive regulation of cell proliferation GO:0008284 10.1 TIMP1 TGFB1 EPO EDN1 CCN2
4 positive regulation of transcription, DNA-templated GO:0045893 10.08 TGFB1 SPP1 SMAD4 SMAD3 SMAD2 EPO
5 negative regulation of gene expression GO:0010629 10.02 TGFB1 SMAD2 EDN1 CCN2
6 protein deubiquitination GO:0016579 10.01 SMAD7 SMAD4 SMAD3 SMAD2
7 positive regulation of cell migration GO:0030335 9.99 TGFB1 SMAD3 EDN1 CCL7
8 heart development GO:0007507 9.99 TGFB1 SMAD2 EDNRA EDN1
9 cytokine-mediated signaling pathway GO:0019221 9.97 TIMP1 TGFB1 PIK3CA F13A1 CXCL2
10 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 TGFB1 EPO CCN2 CCL7
11 in utero embryonic development GO:0001701 9.93 SMAD4 SMAD3 SMAD2 EDNRA EDN1
12 aging GO:0007568 9.91 TIMP1 TGFB1 EPO DCN CCN2
13 response to organic substance GO:0010033 9.89 TIMP1 TGFB1 SPP1
14 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 TGFB1 PIK3CA MAPKAP1
15 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.88 PIK3CA EPO DCN
16 BMP signaling pathway GO:0030509 9.87 TGFB1 SMAD7 SMAD4
17 neutrophil chemotaxis GO:0030593 9.86 EDN1 CXCL2 CCL7
18 response to glucose GO:0009749 9.85 TGFB1 SMAD2 CCN2
19 negative regulation of transforming growth factor beta receptor signaling pathway GO:0030512 9.83 TGFB1 SMAD7 SMAD3 SMAD2
20 cellular response to transforming growth factor beta stimulus GO:0071560 9.8 TGFB1 SMAD7 SMAD3 EDN1
21 transforming growth factor beta receptor signaling pathway GO:0007179 9.8 TGFB1 SMAD7 SMAD4 SMAD3 SMAD2
22 SMAD protein signal transduction GO:0060395 9.78 TGFB1 SMAD4 SMAD3 SMAD2
23 gastrulation GO:0007369 9.76 SMAD4 SMAD3 SMAD2
24 positive regulation of epithelial to mesenchymal transition GO:0010718 9.76 TGFB1 SMAD4 SMAD3 SMAD2
25 developmental growth GO:0048589 9.73 SMAD4 SMAD3 SMAD2
26 ureteric bud development GO:0001657 9.73 TGFB1 SMAD7 SMAD3 SMAD2
27 response to hypoxia GO:0001666 9.73 TGFB1 SMAD4 SMAD3 EPO EDNRA EDN1
28 positive regulation of SMAD protein signal transduction GO:0060391 9.72 TGFB1 SMAD4
29 secondary palate development GO:0062009 9.72 SMAD4 SMAD2
30 lens fiber cell differentiation GO:0070306 9.72 TGFB1 SMAD3
31 wound healing GO:0042060 9.72 TIMP1 TGFB1 SMAD3 SMAD2 DCN
32 pathway-restricted SMAD protein phosphorylation GO:0060389 9.71 TGFB1 SMAD7
33 cell activation GO:0001775 9.71 TIMP1 TGFB1
34 response to transforming growth factor beta GO:0071559 9.7 SMAD4 EDN1
35 response to dexamethasone GO:0071548 9.68 EPO EDN1
36 response to cholesterol GO:0070723 9.68 TGFB1 SMAD2
37 nodal signaling pathway GO:0038092 9.68 SMAD3 SMAD2
38 primary miRNA processing GO:0031053 9.68 SMAD3 SMAD2
39 artery smooth muscle contraction GO:0014824 9.67 EDNRA EDN1
40 pericardium development GO:0060039 9.67 SMAD3 SMAD2
41 endoderm development GO:0007492 9.67 TGFB1 SMAD4 SMAD3 SMAD2
42 embryonic foregut morphogenesis GO:0048617 9.66 SMAD3 SMAD2
43 regulation of glucose transmembrane transport GO:0010827 9.66 EDNRA EDN1
44 response to laminar fluid shear stress GO:0034616 9.65 TGFB1 SMAD7
45 endothelin receptor signaling pathway GO:0086100 9.64 EDNRA EDN1
46 regulation of striated muscle tissue development GO:0016202 9.64 TGFB1 SMAD3
47 common-partner SMAD protein phosphorylation GO:0007182 9.63 TGFB1 SMAD2
48 response to salt GO:1902074 9.63 TGFB1 EDN1
49 positive regulation of extracellular matrix assembly GO:1901203 9.62 TGFB1 SMAD3
50 connective tissue development GO:0061448 9.62 TGFB1 CCN2

Molecular functions related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.36 TIMP1 TGM2 TGFB1 SPP1 SMAD7 SMAD4
2 proximal promoter sequence-specific DNA binding GO:0000987 9.67 SMAD4 SMAD3 SMAD2
3 collagen binding GO:0005518 9.56 SMAD7 SMAD4 SMAD3 DCN
4 R-SMAD binding GO:0070412 9.54 SMAD4 SMAD3 SMAD2
5 enhancer binding GO:0035326 9.52 SMAD3 SMAD2
6 co-SMAD binding GO:0070410 9.51 SMAD3 SMAD2
7 transforming growth factor beta receptor binding GO:0005160 9.5 TGFB1 SMAD3 SMAD2
8 primary miRNA binding GO:0070878 9.48 SMAD3 SMAD2
9 protein-glutamine gamma-glutamyltransferase activity GO:0003810 9.46 TGM2 F13A1
10 transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activity GO:0030618 9.43 SMAD3 SMAD2
11 I-SMAD binding GO:0070411 9.33 SMAD7 SMAD4 SMAD2
12 cytokine activity GO:0005125 9.17 TIMP1 TGFB1 SPP1 EPO EDN1 CXCL2
13 type I transforming growth factor beta receptor binding GO:0034713 9.13 TGFB1 SMAD7 SMAD2

Sources for Nephrogenic Systemic Fibrosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....